Quinidine plasma concentration and exertional arrhythmia

Area of Science:

• Cardiology
• Clinical Pharmacology

Background:

• Exercise-induced arrhythmia, specifically premature contractions, poses a clinical challenge.
• Identifying effective treatments for exercise-induced arrhythmias is crucial for patient management.

Purpose of the Study:

• To evaluate the efficacy of quinidine gluconate in preventing exercise-induced premature contractions.
• To determine the therapeutic plasma concentration and dose-response relationship of quinidine gluconate.

Main Methods:

• Twenty-nine subjects with a history of frequent premature contractions underwent maximal exercise testing.
• Quinidine gluconate was administered orally at doses of 5, 10, or 15 mg/kg, followed by repeat exercise testing.
• Plasma quinidine concentrations were measured, and cardiovascular parameters were monitored.

Main Results:

• A single oral dose of 10 mg/kg quinidine gluconate prevented premature contractions in 5 of 19 subjects and showed partial suppression in others.
• A 15 mg/kg dose further improved prevention in some non-responders, while 5 mg/kg resulted in sub-therapeutic plasma levels.
• Mild toxic effects like malaise and diarrhea were observed at higher quinidine doses (10-15 mg/kg).

Conclusions:

• Quinidine gluconate can prevent exercise-induced premature contractions, with therapeutic plasma levels achieved at 10 mg/kg.
• Dose optimization is necessary to balance efficacy and minimize toxicity.
• The drug's effectiveness was consistent across healthy individuals and those with symptomatic heart disease.